Amedeo Smart

Free Medical Literature Service



Bladder Cancer

  Free Subscription


1 Anticancer Res
1 Biomed Pharmacother
2 BJU Int
1 Braz J Med Biol Res
2 Cancer
1 Cancer Res
1 Cell Cycle
2 Eur Rev Med Pharmacol Sci
1 Expert Opin Biol Ther
1 Int J Clin Oncol
1 Int J Radiat Oncol Biol Phys
3 Int J Urol
1 Int Urol Nephrol
1 J Cancer Res Clin Oncol
1 J Med Chem
1 Med Clin (Barc)
1 Nan Fang Yi Ke Da Xue Xue Bao
1 Nat Commun
2 Oncotarget
1 Pathol Oncol Res
1 Pharmacogenomics
1 Sichuan Da Xue Xue Bao Yi Xue Ban
1 Toxicol In Vitro
1 Urology

    Anticancer Res

  1. TANG X, Wang S, An C, DU P, et al
    Preoperative High Neutrophil-to-Lymphocyte Ratio Is Associated with High-grade Bladder Cancer.
    Anticancer Res. 2017;37:4659-4663.
    >> Share

    Biomed Pharmacother

  2. TESSMANN JW, Buss J, Begnini KR, Berneira LM, et al
    Antitumor potential of 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-1H-pyrazoles in human bladder cancer cells.
    Biomed Pharmacother. 2017;94:37-46.
    >> Share

    BJU Int

  3. WAINGANKAR N, Mallin K, Smaldone M, Egleston BL, et al
    Assessing the relative influence of hospital and surgeon volume on short-term mortality after radical cystectomy.
    BJU Int. 2017;120:239-245.
    >> Share

  4. MILLER C, Campain NJ, Dbeis R, Daugherty M, et al
    Introduction of robot-assisted radical cystectomy within an established enhanced recovery programme.
    BJU Int. 2017;120:265-272.
    >> Share

    Braz J Med Biol Res

  5. CAO JY, Yin HS, Li HS, Yu XQ, et al
    Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells.
    Braz J Med Biol Res. 2017;50:e6207.
    >> Share


  6. CAHN DB, Handorf EA, Ghiraldi EM, Ristau BT, et al
    Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
    Cancer. 2017 Jul 25. doi: 10.1002/cncr.30900.
    >> Share

  7. VETTERLEIN MW, Wankowicz SAM, Seisen T, Lander R, et al
    Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
    Cancer. 2017 Jul 25. doi: 10.1002/cncr.30907.
    >> Share

    Cancer Res

  8. MIAO L, Liu Q, Lin CM, Luo C, et al
    Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors.
    Cancer Res. 2017;77:719-731.
    >> Share

    Cell Cycle

  9. WEN W, Li J, Wang L, Xing Y, et al
    Inhibition of NEDD4 inhibits cell growth and invasion and induces cell apoptosis in bladder cancer cells.
    Cell Cycle. 2017 Jul 26:1-6. doi: 10.1080/15384101.2017.1338220.
    >> Share

    Eur Rev Med Pharmacol Sci

  10. LI MZ, Lai DH, Zhao HB, Chen Z, et al
    SOCS3 overexpression enhances ADM resistance in bladder cancer T24 cells.
    Eur Rev Med Pharmacol Sci. 2017;21:3005-3011.
    >> Share

  11. PAN ZJ, Deng N, Zou ZH, Chen GX, et al
    The effect of curcumin on bladder tumor in rat model.
    Eur Rev Med Pharmacol Sci. 2017;21:884-889.
    >> Share

    Expert Opin Biol Ther

    Nivolumab for the treatment of bladder cancer.
    Expert Opin Biol Ther. 2017 Jul 24:1-7. doi: 10.1080/14712598.2017.1353076.
    >> Share

    Int J Clin Oncol

  13. TANG X, Du P, Yang Y
    The clinical use of neutrophil-to-lymphocyte ratio in bladder cancer patients: a systematic review and meta-analysis.
    Int J Clin Oncol. 2017 Jul 27. doi: 10.1007/s10147-017-1171.
    >> Share

    Int J Radiat Oncol Biol Phys

  14. CHARGARI C, Haie-Meder C, Guerin F, Minard-Colin V, et al
    Brachytherapy Combined With Surgery for Conservative Treatment of Children With Bladder Neck and/or Prostate Rhabdomyosarcoma.
    Int J Radiat Oncol Biol Phys. 2017;98:352-359.
    >> Share

    Int J Urol

  15. SALUJA M, Gilling P
    Intravesical bacillus Calmette-Guerin instillation in non-muscle-invasive bladder cancer: A review.
    Int J Urol. 2017 Jul 25. doi: 10.1111/iju.13410.
    >> Share

  16. KOBATAKE K, Hayashi T, Black PC, Goto K, et al
    Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer.
    Int J Urol. 2017 Jul 22. doi: 10.1111/iju.13389.
    >> Share

    Editorial Comment to Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer.
    Int J Urol. 2017 Jul 21. doi: 10.1111/iju.13402.
    >> Share

    Int Urol Nephrol

  18. MAHMOUD O, El-Assmy A, Kamal M, Ashamallah A, et al
    Is chronic alkali therapy in orthotopic ileal neobladders necessary? A prospective controlled study.
    Int Urol Nephrol. 2017;49:49-53.
    >> Share

    J Cancer Res Clin Oncol

  19. HE X, Hou J, Ping J, Wen D, et al
    Opa interacting protein 5 acts as an oncogene in bladder cancer.
    J Cancer Res Clin Oncol. 2017 Jul 27. doi: 10.1007/s00432-017-2485.
    >> Share

    J Med Chem

  20. ZHANG GH, Yuan JM, Qian G, Gu CX, et al
    Phthalazino[1,2-b]quinazolinones as p53 Activators: Cell Cycle Arrest, Apoptotic Response and Bak-Bcl-xl Complex Reorganization in Bladder Cancer Cells.
    J Med Chem. 2017 Jul 26. doi: 10.1021/acs.jmedchem.6b01769.
    >> Share

    Med Clin (Barc)

  21. MARTINEZ RODRIGUEZ RH, Buisan Rueda O, Ibarz L
    Bladder cancer: Present and future.
    Med Clin (Barc). 2017 Jul 20. pii: S0025-7753(17)30478.
    >> Share

    Nan Fang Yi Ke Da Xue Xue Bao

  22. WANG CY, Nie QW, Zhou X, Huang DX, et al
    [S100A4, a potential therapeutic target on bladder cancer stem cells].
    Nan Fang Yi Ke Da Xue Xue Bao. 2017;37:869-874.
    >> Share

    Nat Commun

  23. KORPAL M, Puyang X, Jeremy Wu Z, Seiler R, et al
    Evasion of immunosurveillance by genomic alterations of PPARgamma/RXRalpha in bladder cancer.
    Nat Commun. 2017;8:103.
    >> Share


  24. WANG X, Cui MM, Xu Y, Liu L, et al
    Decreased mean platelet volume predicts poor prognosis in invasive bladder cancer.
    Oncotarget. 2017 Jul 12. doi: 10.18632/oncotarget.19242.
    >> Share

  25. LI H, Xu Y, Li H
    CD147 as a novel biomarker for predicting the prognosis and clinicopathological features of bladder cancer: a meta-analysis.
    Oncotarget. 2017 Jul 15. doi: 10.18632/oncotarget.19257.
    >> Share

    Pathol Oncol Res

  26. DZOMBETA T, Kruslin B
    High Grade T1 Papillary Urothelial Bladder Cancer Shows Prominent Peritumoral Retraction Clefting.
    Pathol Oncol Res. 2017 Jul 27. doi: 10.1007/s12253-017-0279.
    >> Share


  27. ZUIVERLOON TC, Theodorescu D
    Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer.
    Pharmacogenomics. 2017 Jul 26. doi: 10.2217/pgs-2017-0055.
    >> Share

    Sichuan Da Xue Xue Bao Yi Xue Ban

  28. YANG YB, Bai YJ, Tang Y, Liu ZH, et al
    [Detection of Circulating Tumor Cells in Bladder Cancer by Subtraction Enrichment and Immunostaining-fluorescence in situ Hybridization].
    Sichuan Da Xue Xue Bao Yi Xue Ban. 2017;48:605-609.
    >> Share

    Toxicol In Vitro

  29. WEWERING F, Jouy F, Caliskan S, Kalkhof S, et al
    Hepatic co-cultures in vitro reveal suitable to detect Nrf2-mediated oxidative stress responses on the bladder carcinogen o-anisidine.
    Toxicol In Vitro. 2017;40:153-160.
    >> Share


  30. KOO K, Zubkoff L, Sirovich BE, Goodney PP, et al
    The Burden of Cystoscopic Bladder Cancer Surveillance: Anxiety, Discomfort, and Patient Preferences for Decision Making.
    Urology. 2017 Jul 21. pii: S0090-4295(17)30754.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016